Racial Differences in the Use of Adjuvant Chemotherapy for Breast Cancer in a Large Urban Integrated Health System

Table 5

Logistic regression analysis of predictors of the timing of adjuvant chemotherapy.

	Unadjusted OR (95% C.I.)	Clinical Factors OR* (95% C.I.)	Societal Factors OR* (95% C.I.)	Adjusted OR* (95% C.I.)
African American	1.68 (1.26–2.23)	1.77 (1.31–2.38)	1.15 (0.79–1.67)	1.18 (0.80–1.74)
Age at diagnosis^a	1.01 (1.00–1.03)	1.01 (1.00–1.03)		1.01 (0.99–1.02)
Comorbidity index^b	0.97 (0.79–1.20)	0.87 (0.70–1.08)		0.86 (0.68–1.07)
Mastectomy^c	1.45 (1.09–1.92)	1.42 (1.06–1.91)		1.38 (1.02–1.85)
Deprivation index^d	1.27 (1.15–1.40)		1.22 (1.07–1.39)	1.23 (1.08–1.41)
Medicare^e	1.73 (1.14–2.61)		1.58 (1.04–2.40)	1.34 (0.81–2.23)
Other insurance^e	1.38 (0.64–3.00)		1.11 (0.50–2.43)	1.08 (0.49–2.40)

^∗Models adjusted for all listed variables.
^aContinuous variable.
^bCharlson comorbidity index; continuous variable capped at 3.
^cThe reference group is lumpectomy or partial mastectomy.
^dQuintiles, the least deprived area (quintile 1) is the referent.
^ePrivate insurance is the referent.